Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report ...
HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report report published on Wednesday morning,Benzinga reports. The firm currently ...